CTOs on the Move

Alvogen

www.alvogen.com

 
Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group`s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2,000 employees. North America is Alvogen`s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Taiwan, Russia and China.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.alvogen.com
  • 10 Bloomfield Ave Ste 2
    Pine Brook, NJ USA 07058
  • Phone: 973.796.3400

Executives

Name Title Contact Details

Funding

Alvogen raised $100M on 06/30/2021

Similar Companies

The Health Museum of Cleveland

The Health Museum of Cleveland is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wockhardt USA

Wockhardt USA is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Huyabio

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

Alpharma, LLC

Alpharma, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Graybug Vision

Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.